Skip to main content
    S

    Senti Biosciences Inc (SNTI)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.14
    -0.00 (-2.86%)

    Market Cap: $5.38M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Senti Biosciences Inc (SNTI) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Senti Biosciences reported revenue of $22.00K for the fiscal year ended Dec 31, 2025. That year, net income was -$61.44M with a net margin of -279263.6%, operating cash flow was -$43.44M and free cash flow was -$43.64M. The quarter ended Sep 30, 2026 had revenue of $19.00K and net income of -$11.59M.

    Revenue and Margins

    Over the 6 years to Dec 2025, revenue fell from $85.00K, a compound annual decline of 20.2%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$22.00KN/A100.0%-312631.8%-279263.6%
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$2.56M-40.2%100.0%-3620.7%-2774.6%
    Dec 2022$4.29M+55.2%100.0%-1448.5%-1358.1%
    Dec 2021$2.76M+600.8%100.0%-1464.9%-2003.6%
    Dec 2020$394.00K+363.5%100.0%-6267.5%-5041.1%
    Dec 2019$85.00KN/A-16987.1%-25625.9%-24890.6%
    Annual, fiscal years ended Dec 2019 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Revenue$22.00K$0$2.56M$4.29M$2.76M$394.00K$85.00K
    Cost of revenue$0$0$0$0$0$15.96M$14.52M
    Gross profit$22.00K$0$2.56M$4.29M$2.76M$394.00K-$14.44M
    Research and development$37.59M$34.36M$32.15M$28.14M$21.96M$15.96M$14.52M
    Operating income-$68.78M-$61.04M-$92.73M-$62.08M-$40.45M-$24.69M-$21.78M
    Net income-$61.44M-$52.79M-$71.06M-$58.21M-$55.32M-$19.86M-$21.16M
    EBITDA-$58.92M-$49.85M-$81.91M-$49.09MN/A-$22.71M-$21.36M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$19.00K$17.00K$16.00K$22.00K$0$0$0$5.86M$0$0$0$333.00K
    Gross profit$19.00K$17.00K$16.00K$22.00K$0$0$0-$1.46M$0$0$0-$1.14M
    Operating income-$12.32M-$14.49M-$4.62M-$18.64M-$16.95M-$16.80M-$16.40M-$16.17M-$15.21M-$13.36M-$16.30M-$18.70M
    Net income-$11.59M-$12.75M-$4.22M-$14.47M-$18.13M-$14.73M-$14.11M-$610.00K-$28.87M-$11.20M-$12.11M-$18.72M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $0 by $16.42M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Total assets$51.22M$97.84M$119.48M$180.79M$96.70M$48.34M$35.84M
    Current assets$23.27M$58.96M$71.20M$102.58M$60.19M$31.71M$18.76M
    Cash and equivalents$16.42M$48.28M$35.93M$57.62M$56.03M$30.54M$5.30M
    Total liabilities$45.63M$47.09M$52.57M$53.53M$36.33M$107.06M$17.88M
    Short-term debt$0$4.75M$4.13M$1.99M$1.74M$1.52MN/A
    Shareholder equity$5.59M$25.65M$66.91M$127.26M-$111.46M-$58.71M$17.96M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$28.36M$33.10M$38.24M$51.22M$52.69M$68.54M$82.78M$97.84M$57.72M$86.91M$102.19M$119.48M
    Total liabilities$37.96M$36.51M$35.68M$45.63M$44.56M$43.89M$44.92M$72.19M$41.73M$42.77M$46.09M$52.57M
    Cash and equivalents$5.55M$6.46M$8.94M$16.42M$12.24M$21.58M$33.80M$48.28M$10.48M$15.86M$23.72M$35.93M
    Shareholder equity-$9.60M-$3.40M$2.56M$5.59M$8.12M$24.65M$37.86M$25.65M$15.99M$44.15M$56.09M$66.91M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
    Operating cash flow-$43.44M-$41.40M-$52.40M-$34.90M-$34.63M-$24.17M-$18.38M
    Capital expenditures$196.00K$26.00K$12.04M$41.37M$5.54M$1.16M$2.00M
    Free cash flow-$43.64M-$41.42M-$64.43M-$76.27M-$40.18M-$25.33M-$20.37M
    Dividends paidN/AN/A$404.00K$5.17M$3.89KN/AN/A
    Share repurchases$2.47M$229.00K$0N/AN/AN/AN/A
    Investing cash flow-$184.00K$34.00K$30.08M-$81.96M-$5.54M$11.36M$3.75M
    Financing cash flow$11.76M$53.73M$779.00K$118.55M$68.44M$38.05M$14.01M
    Fiscal years ended Dec 2019 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$6.73M-$14.25M-$7.48M-$6.88M-$9.45M-$13.07M-$14.05M-$13.50M-$7.87M-$8.35M-$11.68M-$7.04M
    Capital expendituresN/AN/A$0$0$0$196.00K$0$11.00K$0$0$15.00K$4.00K
    Free cash flowN/AN/A-$7.48M-$6.88M-$9.45M-$13.27M-$14.05M-$13.52M-$7.87M-$8.35M-$11.70M-$7.04M
    Last 12 quarters

    Frequently Asked Questions About SNTI

    What is Senti Biosciences' annual revenue?

    Senti Biosciences reported revenue of $22.00K for the fiscal year ended Dec 31, 2025.

    Is Senti Biosciences profitable?

    No. Senti Biosciences reported net income of -$61.44M for the fiscal year ended Dec 31, 2025, with a net margin of -279263.6%.

    How much free cash flow does SNTI generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$43.44M minus capital expenditures of $196.00K produced free cash flow of -$43.64M.

    How much debt does Senti Biosciences have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $0 and cash and equivalents of $16.42M.

    What is SNTI's profit margin?

    For the fiscal year ended Dec 31, 2025, Senti Biosciences reported gross margin of 100.0%, operating margin of -312631.8% and net margin of -279263.6%.